Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.
3 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.

CBT-fluoxetine combo therapy outperforms single treatment for hypochondriasis

06 Aug 2017

A recent study has shown the safety, efficacy and tolerance of fluoxetine for hypochondriasis. Moreover, joint treatment with both fluoxetine and cognitive behavioural therapy (CBT) confers a small incremental benefit over a single active treatment.

To determine whether joint treatment provides additional benefit, researchers randomized 195 patients with DSM-IV hypochondriasis to one of four treatments: placebo, CBT, fluoxetine, or joint treatment with fluoxetine and CBT. Analyses focused on hypochondriasis, adverse events, quality of life, functional status and other psychopathology.

At week 24, outcome was assessed among the intent-to-treat patients, with responders defined as having a ≥25-percent improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M).

The Cochran-Armitage trend test assessed the hypothesized pattern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment.

There was a statistically significant predicted pattern of response as shown by the following responder rates: joint treatment group, 47.2 percent; single active treatment group, 41.8 percent; and placebo group, 29.6 percent. There was no significant difference between responder rates for each active treatment and the rate for placebo.

Based on secondary analyses of the Whiteley Index as a continuous measure, fluoxetine was more effective at week 24 in reducing hypochondriasis and had a significantly faster rate of improvement over 24 weeks than placebo. Fluoxetine also led to significantly less anxiety and better quality of life compared with placebo.

Dropout rates were not different between groups. In addition, there was an even distribution of treatment-emergent adverse events.

According to researchers, “[b]ecause approximately 50 percent of patients did not respond to the study treatments, new or more intensive approaches are needed.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 4 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Tristan Manalac, Yesterday
Hormone treatment confers beneficial mood effects in postmenopausal women, according to a recent study, which reports that a transdermal oestradiol plus intermittent micronized progesterone (TE+IMP) treatment regimen is more effective than placebo at reducing depressive symptoms in peri- and postmenopausal women.
3 days ago
Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.